Followers | 283 |
Posts | 1162 |
Boards Moderated | 0 |
Alias Born | 10/04/2020 |
Friday, December 24, 2021 8:25:42 AM
FACT IS WE ARE AT A CRITICAL CROSS ROAD!!
Here's my take:
Dr. Koos needs to come up with some very serious cash immediately to "GET THE SHOW ON THE ROAD!"
Relative to the Canary deal, the $50 Million funding from a key Investor is the fastest way for that to happen.
It seems that the Acquisition he suggested in his 4/27/21 8K is a far gone "not happening" conclusion although I believe he did receive bids on the company but rejected them, thus "change of plan" which is now the Canary deal.
It's important however to keep in mind that FUNDING is still required for those TWO (2) IND's licensed to Oncology Pharma for treating pancreatic & colon cancer via an mRNA vaccine. The amount of DOUGH required for that is NOT LESS than $160 Million. This and the Canary deal are mutually exclusive matters.
I don't see Oncology Pharma raising capital to fund those two (2) INDs for reason CROs don't typically raise money for clinical trials. Their role is focused on performing clinical trials utilizing their internal manpower resources and infrastructure for which they receive royalties upon commercialization of those INDs per their arrangement with Regen/KCL.
The MOMENT OF TRUTH HAS ARRIVED....
Koos needs to CRAP OR GET OFF THE TOILET!
If his Big SHOT Venture Capitalist/Deal Maker reputation holds true, then this shouldn't be a problem.
Sorry to put it this way but this is the present reality in no uncertain terms.
So based on what I'm seeing, Koos needs not less than $210 Million for both the Canary deal AND the two clinical trials to move forward.
If anyone feels I'm missing something here, please enlighten me.
Be well and prosper...
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM